Immutep Announces First Participant Dosed In Phase I Study Of IMP761
Portfolio Pulse from Benzinga Newsdesk
Immutep Limited (NASDAQ: IMMP) has announced the successful dosing of the first participant in its Phase I trial of IMP761, a novel LAG-3 antibody designed to address autoimmune diseases by enhancing the 'brake' function of LAG-3 on T cells. Safety data is expected by year-end, with further data anticipated in the first half of 2025.
August 14, 2024 | 12:05 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Immutep Limited has dosed the first participant in its Phase I trial of IMP761, a novel LAG-3 antibody aimed at treating autoimmune diseases. Safety data is expected by year-end, with further data in the first half of 2025.
The successful dosing of the first participant in a Phase I trial is a significant milestone for Immutep. The anticipation of safety data by year-end and further data in 2025 could generate positive sentiment and potential short-term price appreciation.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100